Dr. Peter Richardson
Executive Vice President and Interim Chief Scientific Officer
Dr. Peter Richardson serves as the company’s Executive Vice President and Interim Chief Scientific Officer, leading the branded research and development, medical affairs, safety, portfolio and project management, and regulatory affairs functions, and he is a member of the company’s executive committee.
Dr. Richardson has more than 30 years of experience in research and development leadership, including building and supporting product development pipelines and clinical program management. Before joining Mallinckrodt in January 2023, Dr. Richardson served as the Executive Vice President and Chief Medical Officer of Antares Pharmaceuticals, Inc., leading the organization’s research and development activities from April 2021 until May 2022. He also held senior leadership positions in research and development at several pharmaceutical companies, including Adare Pharma, where he was Chief Medical Officer President, Adare Development 1; Novartis; and MannKind Corporation.
Dr. Richardson holds a B.Med.Sci. from the University of Nottingham and a BM, BS from the University of Nottingham Medical School. He completed the Stanford University Graduate School of Business’ executive program and is a member of the Royal College of Physicians in the United Kingdom.